{"id":39935,"date":"2025-08-22T15:37:49","date_gmt":"2025-08-22T07:37:49","guid":{"rendered":"https:\/\/flcube.com\/?p=39935"},"modified":"2025-08-22T15:37:51","modified_gmt":"2025-08-22T07:37:51","slug":"zhongsheng-pharmas-onradivir-granted-drug-registration-in-macau","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39935","title":{"rendered":"Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau"},"content":{"rendered":"\n

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317<\/a>) announced that its onradivir tablets have received a Drug Registration Certificate (Registration Number: MAC-07347) from the Drug Administration of the Macau Special Administrative Region Government. Zhongsheng Pharma has partnered with Kexing Biopharma Co., Ltd. (SHA: 688136<\/a>) to commercialize onradivir in Macau, China.<\/p>\n\n\n\n

Innovative Influenza Treatment<\/strong>
Onradivir, developed by Guangdong Raynovent Biotech Co., Ltd., a subsidiary of Zhongsheng Pharmaceutical, is the world’s first influenza RNA polymerase PB2 protein inhibitor. It received marketing approval from China’s National Medical Products Administration (NMPA) in May 2025 for treating uncomplicated influenza A in adults.<\/p>\n\n\n\n

Clinical Trial Success<\/strong>
Head-to-head Phase 3 clinical trials showed that onradivir outperformed the placebo group in the primary endpoint of time to alleviation of seven influenza symptoms (TTAS), as well as in secondary endpoints, including time to relief of single-system or single-symptom indicators and virological indicators. Notably, the median TTAS and time to fever resolution were nearly 10% shorter compared to the oseltamivir group.-Fineline Info & Tech<\/a><\/p>\n\n\n\n